'High-dose' radioiodine therapy in advanced differentiated thyroid carcinoma

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1496-1503

  Menzel, Christian ^a   Grünwald, Frank ^a   Schomburg, Axel ^a   Palmedo, Holger ^a   Bender, Hans ^a   Späth, Georg ^a   Biersack, Hans Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

advanced differentiated thyroid cancer; hematotoxicity; high dose iodine 131 sodium iodide therapy

Indexed keywords

RADIOACTIVE IODINE; SODIUM IODIDE I 131;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HUMAN; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; SODIUM IODIDE; SURVIVAL RATE; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029741529     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hay ID, Bergstrahl EJ, Goellner JR, et al. Presentation and prognosis in 1228 differentiated thyroid cancers: are there important clinical distinctions between typical papillary and follicular tumors? J Endocrinol Invent 1993;16:35 [abstract].
2. Rossi RL, Cady B, Silverman ML, et al. Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg 1986;10:612-622.
3. Harness JK, McLeod MK, Thompson NW, et al. Deaths due to differentiated thyroid cancer: a 46-year perspective. World J Surg 1988;12:623-629.
4. Woolner LB. Thyroid carcinoma: pathologic classification with data on prognosis. Semin Nucl Med 1971;1:481-502.
5. Freitas JE, Gross MD, Ripley S, et al. Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med 1985;15:106-131.
6. Simpson J, McKinney S. Canadian survey of thyroid cancer. Can Med Assoc J 1985;132:25-31.
7. Cetani F, Giardina S, Miccoli P, et al. Papillary thyroid cancer: retrospective analysis of 760 patients. J Endocrinol Invest 1993;16:34 [abstract].
8. Brown AP, Greening WP, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiology 1984;57: 323-327.
9. Niederle B, Roka R, Schemper M, et al. Surgical treatment of distant metastases in differentiated thyroid cancer: indications and results. Surgery 1986;100:1088-1097.
10. Nogushi S, Nogushi A, Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastases. Cancer 1970;26:1053-1059.
11. Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid. A clinicopathological study of 241 patients treated at the University of Florence. Cancer 1985;55:802-828.
12. Ezaki H, Ebihara S, Fujimoto Y, et al. Analysis of thyroid carcinoma based on material registered in Japan during 1977-1986 with special reference to predominance of papillary type. Cancer 1992;70:808-814.
13. Rosen IB, Bowden J, Luk SC, et al. Aggressive thyroid cancer in low-risk age population. Surgery 1987;102:1075-1080.
14. Samaan NA, Schultz PN, Hickey RC. The results of various modalities of treatment of well-differentiated thyroid carcinoma. J Clin Endocrinol Med 1992;75:714-720.
15. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-805.
16. Schlumberger M, Tubiana M, Vathaire FD, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Med 1986;63:960-967.
17. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma. Cancer 1984;53:982-992.
18. Hoie J, Stenwig AE, Kullmann G, et al. Distant metastases in papillary thyroid carcinoma. Cancer 1988;61:1-6.
19. Proye CAG, Dromer DHR, Carnaille BM, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 1992;16:640-646.
20. Rodrigues M, Colarinha PS, Henriques, MR, et al. Complications and side effects of iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1993;34:931 [abstract].
21. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986;59:45-51.
22. Benua RS, Cicale NR, Sonnenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol 1962;87:171-182.
23. Biersack HJ, Helpap B, Koch U, Janson R, Baumgarten C, Winkler C. Should treatment of highly-differentiated thyroid carcinoma be conservative? Nucl Med 1983;22:20-23.
24. Grünwald F, Ruhlmann J, Ammari B, Knopp R, Hotze A, Biersack HJ. Experience with a high-dose concept of differentiated metastatic thyroid cancer therapy. Nuklear-medizin 1988;27:266-271.
25. Miller AB, Hoogstraten B, Staques M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
26. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
27. Halnan KE. The place of non-surgical methods in diagnosis and management and the long-term value in the treatment of thyroid cancer. Br J Surg 1965;52:736-739.
28. Winkler C. Perspectives for treatment of malignant goiters with radioactive iodine. Dtsch Med Wschr 1950;1438-1440.
29. Beierwaltes WH, Nishiyama RH, Thompson NW, et al. Survival time and "cure" in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med 1982;23:561-568.
30. Creutzig H. High- or low-dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987;12:500-503.
31. Hundeshagen H. Post-operative diagnosis and therapy of thyroid cancer by nuclear medicine. Eur J Nucl Med 1983;8:541-545.
32. Waxman A, Ramanna L, Chapman N. The significance of iodine-131 scan dose in patients with thyroid cancer: determination of ablation. J Nucl Med 1981;22:861-865.
33. Maxon III HR, Englaro EE, Thomas SR, et al. Iodine-131 NaI therapy for well-differentiated thyroid cancer - a quantitative dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-1136.
34. Beierwaltes WH, Rabbani R, Dmuchowski C, et al. An analysis of "ablation of thyroid remnants" with radioiodine in 511 patients from 1947-1984: experience at the University of Michigan. J Nucl Med 1984;25:1287-1293.
35. Snyder J, Gorman C, Scanlon P. Thyroid remnant ablation: questionable pursuit of an ill-defined goal. J Nucl Med 1983;24:659-665.
36. Comtois R, Theriault C, Del Veccio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 1993;34:1927-1930.
37. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 1986;27:1519-1527.
38. Rawson RW, Rall JE, Peacock W. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol 1951;11:1128-1142.
39. Rall JE, Alpers JB, Lewallen CG, et al. Radiation pneumonitis and fibrosis: complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. JCEM 1957;17:1263-1276.
40. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-518.
41. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bullmann T, Plamedo H, Ruhlmann J, Kozak B, Biersack HJ. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-319.
42. Grünwald F, Schomburg A, Menzel C, Steinecker S, Späth S, Bockisch A, Fimmers R, Hotze AL, Biersack HJ. Blood count changes after radioiodine treatment in thyroid carcinoma. Med Klin 1994;89:522-528.
43. Schümichen C, Schmitt E, Scheuffele C. Influence of the therapy concept onto the prognosis of thyroid carcinoma. Nuklearmedizin 1983;22:22-105.
44. Günther HH, Schober O, Schwarzrock R, Hundeshagen H. Hematologic long-term modifications after radioiodine therapy in carcinoma of the thyroid gland. II. Modifications of the bone marrow including leucemia. Strahlenther Onkol 1987;163: 475-485.